ClinicalTrials.gg
RecruitingNCT05952050Updated Jul 19, 2023

Different Administration Routes of Dexmedetomidine on Postoperative Delirium

An interventional study of Dexmedetomidine in Dexmedetomidine, Postoperative Delirium and General Anesthesia, sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 65 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
65 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing dexmedetomidine in Emergence Delirium — 30 open to participants now, 31 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Planned enrollment
32nd of 82
120 · median 100
Started
2023
with 9 others
No phase
26 of 82
12 open now
Primary completion
2023-08
later than 0 of 30 live
Registered
42nd of 82
by date

Among the 82 studies testing dexmedetomidine in Emergence Delirium, this one is the 32nd largest by planned enrollment, is one of 10 that started in 2023, is one of 26 with no phase, reaches primary completion later than 0 of the 30 other live ones, and was the 42nd registered.

Emergence Delirium

752 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

30 of the 82 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 44 (31%) stop at 75 or younger; 34 take children under 18; 24 take healthy volunteers.

This study: 65 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

Intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (POD) in elderly patients. Nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. The current study aimed to compare the effect of different administration routes of dexmedetomidine on POD in elderly patients.

03

Conditions studied

  • Dexmedetomidine
  • Postoperative Delirium
  • General Anesthesia

Browse trials for

04

Who can participate

Ages eligible
65 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Older than 65 years; General anesthesia for more than two hours;

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intranasal dexmedetomidine

    Drug: Dexmedetomidine

  • Active comparator
    Intravenous dexmedetomidine

    Drug: Dexmedetomidine

Interventions

06

What researchers measure

Primary outcomes

  1. The frequency of delirium during the first 3 postoperative days

    Time frame: 3 days

Secondary outcomes

  1. The incidence of postoperative sore throat

    Time frame: 3 days

  2. The incidence of sleep quality

    Time frame: 3 days

07

Study locations

1 of 1 sites recruiting
  • Weitao Chen
    Zhongshan, Guangdong 528000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Aug 2023, 0 months later.

Of 186 interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Aug 1, 2023
CompletionEst.
Sep 30, 2023
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05952050
Lead sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Collaborators
Zhongshan Hospital Of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Aug 1, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Jul 19, 2023

Study contacts

Weitao Chen
Contact
540138690@qq.com
18025661798

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion